60 results
6-K
EX-99.1
PPBT
Purple Biotech Ltd
6 Mar 24
Report of Foreign Private Issuer
4:06pm
/ajcr0074519 5T4 is a Tumor Associated Antigen prevalent to several large indications Opportunity of patient stratification strategy (5T4 + ) | 26
Corpo … as a promising therapeutic strategy for numerous cancers NT219 demonstrates a durable and dose - dependent suppression of STAT3 tyrosine phosphorylation
6-K
EX-99.1
PPBT
Purple Biotech Ltd
21 Nov 23
Report of Foreign Private Issuer
4:00pm
is a Tumor Associated Antigen prevalent to several large indications Opportunity of patient stratification strategy (5T4 + ) | 24
Promising Proof o f … emerged as a promising therapeutic strategy for numerous cancers NT219 demonstrates a durable and dose - dependent suppression of STAT3 tyrosine
424B3
PPBT
Purple Biotech Ltd
14 Nov 23
Prospectus supplement
4:13pm
2010 until its acquisition in September 2011. Dr. Rowinsky also served as a drug development and regulatory strategy consultant to the ImClone-Lilly
F-1/A
PPBT
Purple Biotech Ltd
13 Nov 23
Registration statement (foreign) (amended)
4:11pm
acquisition in September 2011. Dr. Rowinsky also served as a drug development and regulatory strategy consultant to the ImClone-Lilly Oncology Business
6-K
EX-99.1
48dtn
2 Nov 23
Purple Biotech Fortifies NT219 Patent Protection
7:04am
F-1
lqbftow
30 Oct 23
Registration statement (foreign)
4:30pm
424B3
vtdr64e5gaj x1
19 Oct 23
Prospectus supplement
4:40pm
6-K
EX-99.1
yrxoq
13 Oct 23
Report of Foreign Private Issuer
7:09am
6-K
EX-99.1
8elu1n wxeihqm6
13 Sep 23
Report of Foreign Private Issuer
8:39am
6-K
EX-99.1
ifl 2lfugffp39kqg
1 May 23
Notice of Annual General Meeting of Shareholders
4:00pm
6-K
EX-99.1
t9ti99xsbv6
19 Apr 23
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
8:17am
6-K
EX-99.1
960fmttkd2tt70 d9xz
9 Nov 22
Report of Foreign Private Issuer
4:11pm
6-K
EX-99.1
biitqq
2 Nov 22
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
7:39am
6-K
EX-99.2
juh08n
4 Aug 22
Purple Biotech Reports Second Quarter 2022 Financial Results
7:31am
6-K
EX-99.1
4301jsbq30
18 Jul 22
Notice of Annual General Meeting of Shareholders
4:25pm
6-K
EX-99.1
ggcd0
6 Jun 22
Report of Foreign Private Issuer
7:33am
6-K
EX-99.1
9urzpjnq1h119pv
4 Feb 22
Purple Biotech Issues Letter to Shareholders
8:31am
6-K
EX-99.1
gsuv 71m6
9 Dec 21
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
7:30am